Insilico Medicine and Byterna Partner to Develop Next-Gen mRNA Tumor Vaccines

On August 20, Insilico Medicine announced a new research collaboration with Byterna Therapeutics, a company specializing in next-generation RNA therapeutics. The partnership aims to combine their expertise in AI-based neoantigen prediction, sequence design, circular mRNA, targeted delivery, automated experimentation, and intelligent manufacturing.

Together, the two companies plan to build an AI-native R&D engine for mRNA, which will be used to explore personalized tumor vaccines and related innovative therapies. By integrating AI-driven design with advanced mRNA platforms, the collaboration seeks to accelerate the development of next-generation cancer treatments.